Raw Material Sourcing 2021

Key considerations and risk management best practice for placenta-derived cell therapy raw materials

Cell & Gene Therapy Insights 2021; 7(10), 1243–1252


Published: 22 October 2021
Ruth Goldberg, Lior Raviv

Ruth Goldberg joined Pluristem in 2009 and currently serves as Compliance and Methods Validation Manager. Ruth has over 14 years of experience in the biotech industry in several leadership positions. She is skilled in Biotechnology, Life Sciences, Quality Assurance, Quality System, CMC, and Pharmaceutical Industry; a strong education professional with PhD in Cell Biology and Immunology, Technion.

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Operations & Development. Prior to that Mr Raviv served as Process development engineer and Projects manager and Product development Team leader at Pluristem. Prior to joining Pluristem and during the years 2010–2011, Mr Raviv held the position of R&D Analytical Researcher at Teva Pharmaceutical Industries. Mr. Raviv holds a M.Med.Sec in pharmacology from the Ben Gurion University and a BSc, in Biotechnology engineering from the Ben Gurion University.